Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression

• Main Authors: Panxia Wang (Author), Minghui Wang (Author), Yuehuai Hu (Author), Jianxing Chen (Author), Yanjun Cao (Author), Cui Liu (Author), Zhongkai Wu (Author), Juan Shen (Author), Jing Lu (Author), Peiqing Liu (Author)
• Format: Book
• Published: Elsevier, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

As an effective anticancer drug, the clinical limitation of doxorubicin (Dox) is the time- and dose-dependent cardiotoxicity. Yes-associated protein 1 (YAP1) interacts with transcription factor TEA domain 1 (TEAD1) and plays an important role in cell proliferation and survival. However, the role of...